Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide

Background and study aims: Angiodysplasias are the main cause of bleeding from the small intestine. Single lesions may be treated by endoscopic coagulation or surgical resection. However, multiple disseminated angiodysplasias are frequently present, making local therapy an unfavorable choice or impossible. Currently there is no established medical treatment available for these patients. Thalidomide is a potent inhibitor of angiogenesis in experimental models. As angiodysplasias are a result of unregulated vessel growth, antiangiogenic treatment may inhibit growth of angiodysplasias.
Patients and methods: We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine. During the previous 12 months patients had experienced 3 - 7 bleeding episodes and had received a mean of 16.7 blood units. Results: After start of treatment with thalidomide at a dose of 100 mg daily, no further bleeding episodes occurred. Although thalidomide was stopped after 3 months, bleeding did not recur and hemoglobin reached and maintained normal levels without further transfusions for the whole observation period (mean follow-up 34 months). Repeat wireless capsule endoscopy after 3 months’ thalidomide demonstrated substantial reductions in the number, size, and color intensity of angiodysplasias.
Conclusion: Thalidomide seems to inhibit growth of intestinal angiodysplasias and may be useful for treatment of patients with bleeding related to angiodysplasias. Wireless capsule endoscopy allows monitoring of the macroscopic effects of antiangiogenic therapy.

References

• 1 Gordon F H, Watkinson A, Hodgson H. Vascular malformations of the gastrointestinal tract.  Best Pract Res Clin Gastroenterol. 2001;  15 41-58
• 2 Lewis B S, Kornbluth A, Waye J D. Small bowel tumours: yield of enteroscopy.  Gut. 1991;  32 763-765
• 3 Ell C, Remke S, May A. et al . The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding.  Endoscopy. 2002;  34 685-689
• 4 Van Gossum A. Obscure digestive bleeding.  Best Pract Res Clin Gastroenterol. 2001;  15 155-174
• 5 van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone.  Lancet. 1990;  335 953-955
• 6 D’Amato R J, Loughnan M S, Flynn E. et al . Thalidomide is an inhibitor of angiogenesis.  Proc Natl Acad Sci USA. 1994;  91 4082-4085
• 7 Hartmann D, Schmidt H, Bolz G. et al . A prospective two-center study comparing wireless capsule endoscopy with intraoperative enteroscopy in patients with obscure GI bleeding.  Gastrointest Endosc. 2005;  61 826-832
• 8 Junquera F, Feu F, Papo M. et al . A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia.  Gastroenterology. 2001;  121 1073-1079
• 9 Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors.  Nat Med. 2003;  9 669-676
• 10 Lee R J, Springer M L, Blanco-Bose W E. et al . VEGF gene delivery to myocardium: deleterious effects of unregulated expression.  Circulation. 2000;  102 898-901
• 11 Junquera F, Saperas E, de Torres I. et al . Increased expression of angiogenic factors in human colonic angiodysplasia.  Am J Gastroenterol. 1999;  94 1070-1076
• 12 Bauditz J, Schachschal G, Wedel S. et al . Thalidomide for treatment of severe intestinal bleeding.  Gut. 2004;  53 609-613
• 13 Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias.  Am J Gastroenterol. 2003;  98 221-222
• 14 Perez-Encinas M, Rabunal-Martinez M J, Bello Lopez J L. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?.  Haematologica. 2002;  87 34-36
• 15 Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.  Oncology. 2002;  16 21-24
• 16 Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors.  Nat Rev Cancer. 2002;  2 727-739